Biogen Inc.
0R1B.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$33.35B
Close$
$361.69
59.2% upside
Current Fair Value
59.2% upsideUndervalued by 59.2% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $33.35 Billion |
|---|---|
| Enterprise Value | $40.51 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $8.83 |
| Beta | 0.16 |
| Outstanding Shares | 147,700,000 |
Return
| Return on Equity | 4.43% |
|---|---|
| Return on Assets | 2.60% |
| Return on Invested Capital | 4.02% |
Valuation & Multiples
| P/E Ratio | 39.74 |
|---|---|
| PEG | -46.95 |
| Price to Sales | 3.39 |
| Price to Book Ratio | 1.79 |
| Enterprise Value to Revenue | 4.04 |
| Enterprise Value to EBIT | 35.78 |
| Enterprise Value to Net Income | 48 |
| Total Debt to Enterprise | 0.21 |
| Debt to Equity | 0.45 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
July 29, 2026
EPS Estimate
$2.94
Average shareholder expectationRevenue Estimate
$2.46 B
Average shareholder expectationNext Earnings Call
Expected Date
October 28, 2026
EPS Estimate
$2.02
Average shareholder expectationRevenue Estimate
$2.64 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Biogen Inc
7,300 employees
CEO: Josephine Price At Biogen, mission is clear: company is pioneer in neuroscience. Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therape...